Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
0.930
-0.020 (-2.11%)
Jan 23, 2025, 12:22 PM EST - Market open
Company Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jeffrey Meckler |
Contact Details
Address: Three Columbus Circle, 15th Floor New York, New York 10019 United States | |
| Phone | 646 427 2727 |
| Website | indaptusrx.com |
Stock Details
| Ticker Symbol | INDP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001857044 |
| CUSIP Number | 45339J105 |
| ISIN Number | US45339J1051 |
| Employer ID | 86-3158720 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer and Director |
| Walt Addison Linscott Esq. | Chief Operating Officer |
| Nir Sassi | Chief Financial Officer, Secretary and Treasurer |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 22, 2025 | D | Notice of Exempt Offering of Securities |
| Jan 14, 2025 | 8-K | Current Report |
| Dec 31, 2024 | EFFECT | Notice of Effectiveness |
| Dec 23, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 6, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 26, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 424B5 | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |